Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.

Lee HY, Tsai AC, Chen MC, Shen PJ, Cheng YC, Kuo CC, Pan SL, Liu YM, Liu JF, Yeh TK, Wang JC, Chang CY, Chang JY, Liou JP.

J Med Chem. 2014 May 22;57(10):4009-22. doi: 10.1021/jm401899x. Epub 2014 May 6.

PMID:
24766560
2.

Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.

Lee HY, Wang LT, Li YH, Pan SL, Chen YL, Teng CM, Liou JP.

Org Biomol Chem. 2014 Nov 28;12(44):8966-76. doi: 10.1039/c4ob00542b.

PMID:
25277250
3.

Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo.

Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC, Pan SL, Teng CM, Liou JP.

PLoS One. 2012;7(8):e43645. doi: 10.1371/journal.pone.0043645. Epub 2012 Aug 22. Erratum in: PLoS One. 2012;7(9). doi: 10.1371/annotation/ab4fff87-6a32-4718-aa4c-91658f164b8d. Huang, Han-Lin [corrected to Huang, Han-Li].

4.

Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.

Yang Z, Wang T, Wang F, Niu T, Liu Z, Chen X, Long C, Tang M, Cao D, Wang X, Xiang W, Yi Y, Ma L, You J, Chen L.

J Med Chem. 2016 Feb 25;59(4):1455-70. doi: 10.1021/acs.jmedchem.5b01342. Epub 2015 Oct 13.

PMID:
26443078
5.

1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.

Liu YM, Lee HY, Chen CH, Lee CH, Wang LT, Pan SL, Lai MJ, Yeh TK, Liou JP.

Eur J Med Chem. 2015 Jan 7;89:320-30. doi: 10.1016/j.ejmech.2014.10.052. Epub 2014 Oct 18.

PMID:
25462248
6.

Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.

Liu YM, Lee HY, Lai MJ, Pan SL, Huang HL, Kuo FC, Chen MC, Liou JP.

Org Biomol Chem. 2015 Oct 28;13(40):10226-35. doi: 10.1039/c5ob01509j. Epub 2015 Aug 26.

PMID:
26309122
7.

Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.

Hiriyan J, Shivarudraiah P, Gavara G, Annamalai P, Natesan S, Sambasivam G, Sukumaran SK.

Anticancer Res. 2015 Jan;35(1):229-37.

PMID:
25550555
8.

tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.

Valente S, Trisciuoglio D, Tardugno M, Benedetti R, Labella D, Secci D, Mercurio C, Boggio R, Tomassi S, Di Maro S, Novellino E, Altucci L, Del Bufalo D, Mai A, Cosconati S.

ChemMedChem. 2013 May;8(5):800-11. doi: 10.1002/cmdc.201300005. Epub 2013 Mar 25.

PMID:
23526814
9.

N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.

Wang H, Yu N, Song H, Chen D, Zou Y, Deng W, Lye PL, Chang J, Ng M, Sun ET, Sangthongpitag K, Wang X, Wu X, Khng HH, Fang L, Goh SK, Ong WC, Bonday Z, St√ľnkel W, Poulsen A, Entzeroth M.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1403-8. doi: 10.1016/j.bmcl.2009.01.041. Epub 2009 Jan 19.

PMID:
19181524
10.

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, Bonday Z, Goh KC, Hentze H, Hart S, Wang H, Ethirajulu K, Wood JM.

Mol Cancer Ther. 2010 Mar;9(3):642-52. doi: 10.1158/1535-7163.MCT-09-0689. Epub 2010 Mar 2.

11.

Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.

Cheng J, Qin J, Guo S, Qiu H, Zhong Y.

Bioorg Med Chem Lett. 2014 Oct 1;24(19):4768-72. doi: 10.1016/j.bmcl.2014.06.080. Epub 2014 Jul 5.

PMID:
25182565
12.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH.

Mol Cancer Ther. 2008 May;7(5):1054-65. doi: 10.1158/1535-7163.MCT-07-2347.

13.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.

Mol Cancer Ther. 2008 Apr;7(4):759-68. doi: 10.1158/1535-7163.MCT-07-2026.

14.

Design, synthesis and bioevalution of novel benzamides derivatives as HDAC inhibitors.

Li Y, Zhou Y, Qian P, Wang Y, Jiang F, Yao Z, Hu W, Zhao Y, Li S.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):179-82. doi: 10.1016/j.bmcl.2012.10.114. Epub 2012 Nov 5.

PMID:
23206867
15.

Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.

Thaler F, Varasi M, Abate A, Carenzi G, Colombo A, Bigogno C, Boggio R, Zuffo RD, Rapetti D, Resconi A, Regalia N, Vultaggio S, Dondio G, Gagliardi S, Minucci S, Mercurio C.

Eur J Med Chem. 2013 Jun;64:273-84. doi: 10.1016/j.ejmech.2013.03.061. Epub 2013 Apr 10.

PMID:
23644210
16.

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.

Cincinelli R, Musso L, Giannini G, Zuco V, De Cesare M, Zunino F, Dallavalle S.

Eur J Med Chem. 2014 May 22;79:251-9. doi: 10.1016/j.ejmech.2014.04.021. Epub 2014 Apr 8.

PMID:
24742384
17.

Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.

Lai MJ, Huang HL, Pan SL, Liu YM, Peng CY, Lee HY, Yeh TK, Huang PH, Teng CM, Chen CS, Chuang HY, Liou JP.

J Med Chem. 2012 Apr 26;55(8):3777-91. doi: 10.1021/jm300197a. Epub 2012 Apr 5.

18.

Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.

Wang H, Yu N, Chen D, Lee KC, Lye PL, Chang JW, Deng W, Ng MC, Lu T, Khoo ML, Poulsen A, Sangthongpitag K, Wu X, Hu C, Goh KC, Wang X, Fang L, Goh KL, Khng HH, Goh SK, Yeo P, Liu X, Bonday Z, Wood JM, Dymock BW, Kantharaj E, Sun ET.

J Med Chem. 2011 Jul 14;54(13):4694-720. doi: 10.1021/jm2003552. Epub 2011 Jun 16.

PMID:
21634430
19.

Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.

Li X, Liu JL, Yang XH, Lu X, Zhao TT, Gong HB, Zhu HL.

Bioorg Med Chem. 2012 Jul 15;20(14):4430-6. doi: 10.1016/j.bmc.2012.05.031. Epub 2012 May 26.

PMID:
22705022
20.

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C.

J Med Chem. 2010 Mar 11;53(5):2000-9. doi: 10.1021/jm901453q.

PMID:
20143778

Supplemental Content

Support Center